Immix Biopharma (IMMX) Fundamental Analysis: Revenue, Earnings & Valuation

3.35 / 10

Netural

Fundamental analysis scores 3.4/10, indicating weak fundamentals. Strengths include high accounts receivable turnover, solid interest coverage, strong inventory turnover, favorable revenue‑to‑market‑value and PB‑ROE. Weaknesses are low income‑tax‑to‑profit ratio, poor fixed‑asset turnover and negative asset‑to‑market‑value, suggesting challenges.

Analysis Checks(7/10)

Revenue-MV

Value-0.28

Score3/3

Weight43.56%

1M Return8.83%

Total operating revenue (YoY growth rate %)

Value78.05

Score2/3

Weight2.31%

1M Return0.58%

Inventory turnover ratio

Value47.57

Score3/3

Weight-2.47%

1M Return-0.67%

Accounts receivable turnover ratio

Value25.89

Score2/3

Weight-2.45%

1M Return-0.65%

PB-ROE

Value1.81

Score2/3

Weight48.84%

1M Return8.98%

Income tax / Total profit (%)

Value-0.14

Score1/3

Weight-2.24%

1M Return-0.59%

Fixed assets turnover ratio

Value7899.90

Score1/3

Weight-4.59%

1M Return-1.28%

Interest coverage ratio (EBIT / Interest expense) (%)

Value15.64

Score2/3

Weight-2.76%

1M Return-0.73%

Cost of sales ratio (%)

Value70.30

Score2/3

Weight-2.71%

1M Return-0.74%

Asset-MV

Value-0.48

Score0/3

Weight22.52%

1M Return4.88%

Is IMMX undervalued or overvalued?

IMMX scores 3.35/10 on fundamentals and holds a Fair valuation at present. Backed by its -174.29% ROE, 0.00% net margin, -16.03 P/E ratio, 5.03 P/B ratio, and -17.11% earnings growth, these metrics solidify its Netural investment rating.